NY A01321

Expands collaborative drug therapy management to allow pharmacists to enter into written agreements with nurse practitioners, in addition to physicians, for reviewing, evaluating, and managing patient drug therapy

Makes the pharmacist collaborative drug therapy management program permanent by removing the July 1, 2026 expiration date

Broadens eligible facilities from teaching hospitals and general hospitals to all hospitals as defined under public health law, plus allows up to 15 community-practice sites selected by the department

Permits pharmacists under collaborative agreements to adjust drug regimens, order disease-related laboratory tests, and perform routine patient monitoring functions such as checking vital signs, with physician or nurse practitioner oversight

Requires patient written consent for collaborative drug therapy management and mandates disclosure to the patient's primary physician or nurse practitioner and other treating healthcare providers